Header Logo

Connection

Noluthando Mwelase to HIV Infections

This is a "connection" page, showing publications Noluthando Mwelase has written about HIV Infections.
Connection Strength

1,004
  1. Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment. J Int AIDS Soc. 2025 Feb; 28(2):e26422.
    View in: PubMed
    Score: 0,067
  2. High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort. J Int AIDS Soc. 2024 Dec; 27(12):e26389.
    View in: PubMed
    Score: 0,066
  3. Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067. J Acquir Immune Defic Syndr. 2024 Nov 01; 97(3):216-225.
    View in: PubMed
    Score: 0,065
  4. Adverse Pregnancy Outcomes Among Women with Human Immunodeficiency Virus Taking Isoniazid Preventive Therapy During the First Trimester. Clin Infect Dis. 2024 03 20; 78(3):667-673.
    View in: PubMed
    Score: 0,063
  5. Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings. J Acquir Immune Defic Syndr. 2023 10 01; 94(2):165-173.
    View in: PubMed
    Score: 0,061
  6. Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
    View in: PubMed
    Score: 0,056
  7. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. J Antimicrob Chemother. 2021 02 11; 76(3):718-721.
    View in: PubMed
    Score: 0,051
  8. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics. 2021 01; 31(1):17-27.
    View in: PubMed
    Score: 0,050
  9. Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy. J Acquir Immune Defic Syndr. 2020 08 01; 84(4):422-429.
    View in: PubMed
    Score: 0,049
  10. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis. 2020 02 03; 70(4):549-556.
    View in: PubMed
    Score: 0,047
  11. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 03 14; 380(11):1001-1011.
    View in: PubMed
    Score: 0,044
  12. Inflammation and micronutrient biomarkers predict clinical HIV treatment failure and incident active TB in HIV-infected adults: a case-control study. BMC Med. 2018 09 24; 16(1):161.
    View in: PubMed
    Score: 0,043
  13. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV. 2018 04; 5(4):e172-e180.
    View in: PubMed
    Score: 0,041
  14. Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):e71-e79.
    View in: PubMed
    Score: 0,039
  15. Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin Trials. 2017 05; 18(3):100-109.
    View in: PubMed
    Score: 0,039
  16. Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation. J Acquir Immune Defic Syndr. 2016 10 01; 73(2):123-9.
    View in: PubMed
    Score: 0,037
  17. Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. J Infect Dis. 2016 Jul 01; 214(1):65-72.
    View in: PubMed
    Score: 0,036
  18. Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings. J Infect Dis. 2016 Apr 01; 213(7):1074-8.
    View in: PubMed
    Score: 0,035
  19. Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation. Clin Infect Dis. 2015 Jul 01; 61(1):102-10.
    View in: PubMed
    Score: 0,034
  20. Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy. Nutrients. 2014 Nov 13; 6(11):5061-78.
    View in: PubMed
    Score: 0,033
  21. Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings. PLoS One. 2014; 9(4):e95164.
    View in: PubMed
    Score: 0,032
  22. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis. 2018 07 02; 67(2):251-260.
    View in: PubMed
    Score: 0,011
  23. Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. Clin Nutr. 2016 Feb; 35(1):183-189.
    View in: PubMed
    Score: 0,008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.